Mythic Therapeutics is a product-platform company developing a pipeline of antibody-drug conjugates (ADCs) designed to exhibit unparalleled therapeutic index and efficacy. The company’s FateControl technology specifically enhances ADC uptake in targeted tissues by manipulating the fate of the ADC within the cell, thereby expanding the disease and patient profiles that can be treated with Mythic’s ADCs.
Location: United States, Massachusetts, Waltham
Total raised: $103M
Investors 8
Funding Rounds 1
| Date | Series | Amount | Investors |
| 15.12.2021 | Series B | $103M | - |
Mentions in press and media 4
| Date | Title | Description |
| 16.12.2021 | Reddit is—finally—going public | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. It’s official. Reddit announced yesterday that it had confidentially filed for an IPO with the SE... |
| 15.12.2021 | Mythic Therapeutics Launches with New Approach to Improving Antibody Drug Conjugate Performance, Backed by $103 Million in Series B Financing | Mythic Therapeutics today announced its launch to develop smarter and safer antibody-drug conjugates (ADCs) with an oversubscribed Series B financing round of $103 million. Viking Global Investors led the round, along with new investors inc... |
| 15.12.2021 | The top policy battles for 2022, explained | This is the web version of Term Sheet, a daily newsletter on the biggest deals and dealmakers. Sign up to get it delivered free to your inbox. I know it’s only a Wednesday, but I’ve been quite reflective the past 24 hours as I prepare for T... |
| - | Startup Mythic Therapeutics emerges with $103M to control fate of ADC cancer drugs | The concept of an antibody drug conjugate is straightforward enough: a cancer-killing drug payload attached to a targeting antibody that directs the molecule to cancer cells. Though these targeted therapies have established a place in cance... |